Gadobenate Dimeglumine is administered by a qualified healthcare professional in a hospital or imaging center setting. You will not take this medication at home.

• Administration: It is given as a single intravenous (IV) injection into a vein, typically in your arm. The injection is performed either manually by hand or using an automatic injector system.
• Dosage: The dose is calculated precisely based on your body weight. For adults and children (above 2 years of age), the typical dose is 0.1 mmol per kilogram (kg) of body weight, which is often 0.2 mL per kg of the 0.5 M solution. For children below 2 years of age, the recommended dosage range is 0.1 to 0.2 mL/kg.
• Timing: The injection is timed carefully with your MRI scan. For general CNS (brain/spine) imaging, it’s given as a rapid injection. For liver imaging, there might be dynamic scans immediately after injection, followed by delayed scans (e.g., 40-120 minutes later) to capture the liver-specific enhancement.
• Saline Flush: After the injection, a saline (salt water) flush is given through the IV line to ensure all the contrast agent enters your bloodstream and to clear the line.
• Monitoring: You will be closely monitored during and for a period after the injection for any immediate reactions.

Always follow any specific preparation instructions given by your doctor or the imaging center for your MRI scan.

Gadobenate Dimeglumine works by changing the magnetic signals of water molecules in your body, which the MRI machine then detects and uses to create images. Like other gadolinium-based contrast agents, it contains a gadolinium ion that acts as a powerful “paramagnetic” substance. When Gadobenate Dimeglumine is injected into your vein, it quickly travels throughout your bloodstream. Because of its special chemical structure, it affects the relaxation times of nearby water protons, making tissues where it collects appear brighter on the MRI scan, especially in T1-weighted images.

What makes Gadobenate Dimeglumine unique is its liver-specific property. A portion of the injected dose is actively taken up by healthy liver cells (hepatocytes) and then excreted into the bile. This allows for both:

• Dynamic imaging: Where blood vessels and initial blood flow are highlighted.
• Delayed, liver-specific imaging: Where the contrast agent has been taken up by normal liver cells but not by abnormal areas (like many tumors), making these abnormal areas stand out as darker regions against a brighter background. This helps in better detection and characterization of liver lesions.
• Gadobenate Dimeglumine alters water molecule magnetic properties, enhancing MRI signals.
• It is taken up by healthy liver cells (hepatocytes).
• This allows for both dynamic (blood flow) and delayed (liver-specific) imaging.
• Helps abnormal liver areas (like tumors) stand out against healthy tissue.

Like all medications, Gadobenate Dimeglumine can cause side effects. Most reactions are mild and resolve on their own. Common side effects include:

• Headache: This is a frequently reported side effect.
• Nausea or vomiting.
• Dizziness or lightheadedness.
• Unusual taste in the mouth.
• Feeling of warmth, coldness, or pain at the injection site.

More serious, but less common, side effects that require immediate medical attention include:

• Allergic (Hypersensitivity) Reactions: These can range from mild (rash, hives, itching) to severe (difficulty breathing, swelling of the face, lips, tongue, or throat, tightness in the chest, low blood pressure, or collapse).
• Nephrogenic Systemic Fibrosis (NSF): A rare but very serious condition that causes hardening and thickening of the skin and other organs. It is primarily a risk for patients with severe kidney problems.
• Acute Kidney Injury: Though rare, it can worsen kidney function in individuals with pre-existing kidney disease.
• Seizures or convulsions.
• Heart problems: Palpitations, irregular heartbeat, or chest pain.
• Changes in skin color or texture (signs of NSF).
• Muscle weakness or joint stiffness (signs of NSF).

Always report any new, worsening, or severe symptoms to the healthcare professionals immediately during or after your MRI scan.

Before you receive Gadobenate Dimeglumine, your doctor and the imaging team will thoroughly evaluate your medical history and current health status, paying close attention to these warnings:

• Kidney Function (Renal Impairment): This is the most crucial precaution. Gadolinium-based contrast agents, including Gadobenate Dimeglumine, increase the risk of Nephrogenic Systemic Fibrosis (NSF) in patients with impaired kidney function. Your doctor will likely order a blood test to check your kidney function (eGFR) before administering Gadobenate Dimeglumine. While Gadobenate Dimeglumine is considered to have a lower risk of NSF than some older GBCAs, it should still be used with extreme caution or avoided in patients with severe kidney disease or acute kidney injury unless absolutely essential.
• Allergic History: Inform the healthcare team if you have a history of allergies, asthma, or previous reactions to any contrast agents, dyes, or other medications. Measures will be in place to manage severe allergic reactions.
• Gadolinium Retention: Small amounts of gadolinium can remain in the body, including the brain, bones, and skin, for months or even years after receiving GBCAs. The long-term effects of this retention are not fully understood, but current data suggests minimal risk in people with normal kidney function.
• Pregnancy and Breastfeeding: Inform your doctor if you are pregnant or breastfeeding. Gadobenate Dimeglumine should be used in pregnant women only if the diagnostic information is essential and cannot be obtained without it. For breastfeeding mothers, the amount that passes into breast milk is very small, but you may choose to temporarily interrupt breastfeeding.
• Intrathecal Use: Gadobenate Dimeglumine is not approved for intrathecal (spinal) use. Administration into the spine can cause serious adverse reactions.

Gadobenate Dimeglumine generally has a low risk of drug-drug interactions because it is not significantly metabolized (broken down) by the body’s enzyme systems. It is mainly eliminated unchanged, either by the kidneys or through the liver into bile. However, it’s still very important to inform your doctor, radiologist, and the healthcare team about all medications you are currently taking, including prescription drugs, over-the-counter medicines, herbal products, and supplements.

• No significant metabolic interactions: Gadobenate Dimeglumine does not typically interfere with how other drugs are metabolized.
• Kidney or Liver Health: While not direct drug interactions, conditions or medications that significantly impair kidney or liver function are important for your doctor to know. These conditions affect how Gadobenate Dimeglumine is eliminated from the body and can influence the risk of certain side effects like Nephrogenic Systemic Fibrosis (NSF).
• Other Contrast Agents: Do not receive other contrast agents without informing your healthcare provider.
• Allergies: Always mention any known allergies, especially to other contrast agents or dyes.

The healthcare team needs a complete picture of your medical history and current medications to ensure the safest possible administration of Gadobenate Dimeglumine.

The dosage of Gadobenate Dimeglumine (MultiHance) is precisely determined by the healthcare professional who orders and administers the MRI, based on several factors.

• Standard Dose for CNS and MRA (Adults and Children > 2 years): The recommended dose is 0.1 mmol/kg (0.2 mL/kg) of body weight, given as a rapid intravenous injection. This is followed by a saline flush.
• Standard Dose for CNS (Children < 2 years): The recommended dosage range is 0.1 to 0.2 mL/kg given as a rapid intravenous injection.
• Liver Imaging (Adults and Children > 2 years): For liver-specific imaging, the recommended dose is often 0.05 mmol/kg (0.1 mL/kg), which is lower than for general CNS/MRA imaging, taking advantage of its high relaxivity and liver uptake. The lowest dose that provides sufficient enhancement should be used.
• Administration: It’s a single injection for a single MRI examination.
• Repeat Doses: Generally, repeated doses within a short timeframe (e.g., within 7 days) are not recommended unless absolutely necessary, especially in patients with kidney impairment.

Your medical team will calculate the exact amount needed for your weight and the specific type of MRI scan being performed.

Gadobenate Dimeglumine (MultiHance) is a prescription-only medication (POM). It is never available over-the-counter. Due to its nature as a sophisticated contrast agent used in specialized medical imaging, its intravenous administration, the need for careful patient screening (particularly for kidney function and allergy history), and the potential for serious, albeit rare, side effects like Nephrogenic Systemic Fibrosis (NSF), Gadobenate Dimeglumine must be prescribed by a licensed medical doctor. This prescription is typically ordered by the radiologist or the physician who refers you for the MRI scan. The administration of Gadobenate Dimeglumine and the MRI procedure itself are performed by trained healthcare professionals in a hospital or an approved diagnostic imaging center under strict medical supervision. You will not receive this medication to take home.

• Gadobenate Dimeglumine is a prescription-only medication (POM).
• It is not available over-the-counter.
• Requires a valid prescription from a licensed doctor, typically a radiologist or referring physician.
• Administered intravenously only by trained healthcare professionals in a hospital or imaging center.
• Patient screening (especially kidney health) is a mandatory step before its use

1. What is Gadobenate Dimeglumine?

• A gadolinium-based contrast agent used in magnetic resonance imaging (MRI) to enhance image quality.

2. How is Gadobenate Dimeglumine administered?

• By intravenous injection, usually during MRI procedures.

3. What is the typical indication for Gadobenate Dimeglumine?

• To improve the visualization of lesions and vascular structures in MRI, especially in some liver studies.

4. What should patients do before a gadolinium-enhanced MRI?

• Inform the clinician about kidney function, pregnancy status, allergies, and any prior reactions to contrast agents.

5. What are common side effects?

• Nausea, headache, flushing, or a metallic taste; severe reactions are rare.

6. What are serious risks associated with Gadobenate Dimeglumine?

• Nephrogenic systemic fibrosis (NSF) is a concern with some gadolinium agents in patients with severe kidney disease, though risk varies by agent; discuss kidney function with your doctor.

7. How does Gadobenate Dimeglumine differ from other gadolinium agents?

• It has partial hepatobiliary uptake with some enhanced liver imaging potential and a different pharmacokinetic profile.

8. Can Gadobenate Dimeglumine be used in pregnancy?

• Generally, use only if the potential benefit justifies the potential risk; discuss with your clinician.

9. Is Gadobenate Dimeglumine safe for people with kidney disease?

• Kidney function should be evaluated; dosing and agent choice may be adjusted or alternatives considered.

10. How should I monitor after administration?

• Monitor for adverse reactions for a short period post-injection; report any new symptoms such as shortness of breath or swelling.

11. Can Gadobenate Dimeglumine be re-administered for future MRIs?

• Yes, when clinically indicated, but cumulative exposure and kidney function are considered.

12. Are there interactions with other medications?

• Generally uncommon, but inform your provider of all medications and supplements.

13. What are common non-serious adverse events?

• Headache, dizziness, nausea, or metallic taste.

14. How is Gadobenate Dimeglumine excreted?

• Primarily via the kidneys (urine); a portion may be cleared hepatically.

15. Can it affect MRI results in children?

• It can be used in pediatric imaging when indicated; pediatric dosing is weight-based and safety profiles are considered.

16. What happens if a dose is missed?

• If a planned MRI is delayed or canceled, discuss with your provider about rescheduling and dose timing.

17. Is there a risk of gadolinium deposition with Gadobenate Dimeglumine?

• Gadolinium-based agents may leave trace amounts in tissues; clinical significance is still under study and should be discussed with a clinician.

18. How long does the contrast stay in the body?

• Most of the dose is cleared within hours to a day, depending on kidney function.

19. Can Gadobenate Dimeglumine cause allergic-type reactions?

• Rarely, but true allergic reactions can occur; facilities are prepared to manage them.

20. What should I tell my doctor before receiving Gadobenate Dimeglumine?

• Kidney function, pregnancy status, allergies, prior reactions to contrast, and current medications.